Literature DB >> 26611554

Corticosteroids in Myositis and Scleroderma.

Anna Postolova1, Jennifer K Chen2, Lorinda Chung3.   

Abstract

Idiopathic inflammatory myopathies (IIMs) involve inflammation of the muscles and are classified by the patterns of presentation and immunohistopathologic features on skin and muscle biopsy into 4 categories: dermatomyositis, polymyositis, inclusion body myositis, and immune-mediated necrotizing myopathy. Systemic corticosteroid (CS) treatment is the standard of care for IIM with muscle and organ involvement. The extracutaneous features of systemic sclerosis are frequently treated with CS; however, high doses have been associated with scleroderma renal crisis in high-risk patients. Although CS can be effective first-line agents, their significant side effect profile encourages concomitant treatment with other immunosuppressive medications to enable timely tapering. Published by Elsevier Inc.

Entities:  

Keywords:  Corticosteroids; Glucocorticoids; Idiopathic inflammatory myopathies; Morphea; Myositis; Scleroderma; Systemic sclerosis

Mesh:

Substances:

Year:  2015        PMID: 26611554      PMCID: PMC5481159          DOI: 10.1016/j.rdc.2015.08.011

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  54 in total

1.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

Review 2.  Review of dermatomyositis: establishing the diagnosis and treatment algorithm.

Authors:  Lindsay C Strowd; Joseph L Jorizzo
Journal:  J Dermatolog Treat       Date:  2012-07-25       Impact factor: 3.359

3.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

4.  Guidelines of care for dermatomyositis. American Academy of Dermatology.

Authors:  L A Drake; S M Dinehart; E R Farmer; R W Goltz; G F Graham; M K Hordinsky; C W Lewis; D M Pariser; J W Skouge; S B Webster; D C Whitaker; B Butler; B J Lowery; R D Sontheimer; J P Callen; C Camisa; T T Provost; D L Tuffanelli
Journal:  J Am Acad Dermatol       Date:  1996-05       Impact factor: 11.527

Review 5.  Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.

Authors:  Bornstein Gil; Lidar Merav; Langevitz Pnina; Grossman Chagai
Journal:  Clin Rheumatol       Date:  2015-04-07       Impact factor: 2.980

Review 6.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

7.  Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients.

Authors:  R K Winkelmann; D W Mulder; E H Lambert; F M Howard; G R Diessner
Journal:  Mayo Clin Proc       Date:  1968-08       Impact factor: 7.616

8.  Linear scleroderma "en coup de sabre" coexisting with plaque-morphea: neuroradiological manifestation and response to corticosteroids.

Authors:  I Unterberger; E Trinka; K Engelhardt; A Muigg; P Eller; M Wagner; N Sepp; G Bauer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-05       Impact factor: 10.154

Review 9.  Myositis autoantibodies and clinical phenotypes.

Authors:  Anna Ghirardello; Elisabetta Borella; Marianna Beggio; Franco Franceschini; Micaela Fredi; Andrea Doria
Journal:  Auto Immun Highlights       Date:  2014-08-23

Review 10.  The diagnostic utility of autoantibodies in adult and juvenile myositis.

Authors:  Sarah L Tansley; Zoe E Betteridge; Neil J McHugh
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

View more
  6 in total

Review 1.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis.

Authors:  Michele Iudici; Serena Vettori; Barbara Russo; Veronica Giacco; Domenico Capocotta; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2016-05-17       Impact factor: 2.980

3.  A neoteric multidrug combination: novel approach to limited cutaneous systemic scleroderma involving the face.

Authors:  M Hari Kumar; M Siva Kumar; Sabitha Hari Kumar; Kingsly Selva Kumar
Journal:  BMJ Case Rep       Date:  2016-03-31

4.  Juvenile Scleroderma: A Referral Center Experience.

Authors:  Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Arch Rheumatol       Date:  2018-01-18       Impact factor: 1.472

5.  Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.

Authors:  Mahdieh Fazel; Patrick M Jedlowski
Journal:  Case Reports Immunol       Date:  2019-04-30

6.  Yoga as a Novel Adjuvant Therapy for Patients with Idiopathic Inflammatory Myopathies.

Authors:  Steve S Kong; Thanh Pham; Allyson Fortis; Alpa Raval; Neha Bhanusali
Journal:  Int J Yoga       Date:  2021-02-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.